Jim Simons
CDAK

Jim Simons’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Jim Simons’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300,852
Closed -$120K – 4526
2022
Q4 		$120K Buy
300,852
+232,552
+340% +$153K ﹤0.01% 3563
2022
Q3 		$53K Sell
68,300
-31,198
-31% -$65.5K ﹤0.01% 3745
2022
Q2 		$287K Buy
99,498
+80,998
+438% +$284K ﹤0.01% 3479
2022
Q1 		$116K Buy
+18,500
New +$116K ﹤0.01% 3767

Other funds holding CDAK

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return
PM
Parametrica Management Wanchai, Hong Kong $128M AUM 171.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jim Simons's CDAK Position: Q1 2023 in Review

Jim Simons sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2023, closing a stake of 300,852 shares — an estimated $120K sold.

Jim Simons first reported a position in CDAK in Q1 2022 and held it in 4 quarters. The position peaked at $287K in Q2 2022. 27 funds tracked by Wall St. Rank hold CDAK as of Q1 2023.

  • Jim Simons reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Jim Simons sold 300,852 Codiak BioSciences, Inc. Common Stock shares in Q1 2023, an estimated $120K.
  • Jim Simons first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Jim Simons's Codiak BioSciences, Inc. Common Stock position peaked at $287K in Q2 2022.
  • 27 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2023.

Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.